Introduction
Influenza viruses circulate all over the world with an annual attack rate of 5 10% in adults and 20 30% in children. Influenza virus infection is a serious public health problem that causes worldwide 3 to 5 million cases of severe illness and about 250 000 to 500 000 deaths per year. Therefore, it is especially recommended for the elderly and children to vaccinate against influenza annually [1] . Currently used vaccines stimulate the production of antibodies directed against viral surface glycoproteins, in particular hemagglutinin (HA) and neuraminidase (NA) [2] . However, due to antigenic drift, these antibodies fail to protect against new antigenic variants of the same type or subtype and are rarely cross reactive against other influenza virus strains [3] . Thus, annual vaccine reformulation is necessary to ultimately maintain immunity against seasonal influenza viruses [4, 5] . Furthermore, antigenic drift renders uniform population wide vaccination campaigns, that have led to the control of measles and smallpox, ineffective for influenza virus [6] . Clearly, there is a great need for a vaccine that induces heterosubtypic protection against all influenza A viruses.
This heterosubtypic immunity is generally mediated by cytotoxic T lymphocytes (CTLs) [7] . It was demonstrated before, that patients with measurable T cell responses were able to clear the virus effectively, even though they lack anti influenza virus specific antibodies for the particular influenza virus subtype [8] . The majority of influenza A virus induced CD8 + cytotoxic T cells are directed against internal virus determinants like the nucleoprotein (NP) and the matrix protein 1 (M1) that are highly conserved [9] . In contrast to antibody responses that are specific for each virus subtype, CTLs exhibit the desired exten sive cross reactivity between different influenza A virus strains that could help to attenuate a new pandemic outbreak of influenza [8, 10] . As influenza A viruses cause respiratory tract infection, the mucosal surface is the site of initial virus replication. Current vaccines induce serum neutralizing antibodies but only little local immune response after parenteral immunization with inactivated virus. Intranasal immu nization on the other hand was shown to be able to stimulate mucosal immunity and CTL responses, which serve as a first line immune defense by suppressing initial viral replication in the respiratory epitheli um [7, 11, 12] . Nguyen et al. could show that mice immunized with a live nonpathogenic influenza virus strain via the pulmonary route survived challenge with a pathogenic influenza strain in contrast to mice that were immunized intravenously or intraperitoneally, which showed only minor protection [13] . CTLs specific for epitopes derived from viral proteins that are highly conserved throughout influenza A virus strains can be induced with the help of synthetic peptides. These peptide vaccines are capable of inducing robust CTL responses and provide several advantages. They can be produced economically on a large scale and be stored lyophilized at room temperature. Additionally, a multi epitope vaccine can protect containing PLGA MS as determined by BCA assay. Assessed amounts of M1 peptide were compared to theoretical maximal loading and given in % encapsulation of peptide input (left) and % of peptide released in aqueous medium during 6 days also based on the peptide input used for particle production (right) against antigenic drift and increase the clonality of the T cell response. In contrast to many live or attenuated vaccines, peptide based vaccines are devoid of infectious material [11, 14, 15] . However, vaccination with pep tides instead of virus via the mucosal route bears the danger of in ducing tolerance or hypersensitivity, as most antigens introduced are poorly immunogenic. A prerequisite for a successful vaccination is therefore the use of adjuvants and an effective delivery system [16] . We and others have investigated biodegradable poly(D,L lactide co glycolide) microspheres (PLGA MS) as antigen delivery systems targeting dendritic cells (DCs) and macrophages in vitro and in vivo [17, 18] . Encapsulated peptides are protected from proteolytic degradation and delivered to phagocytic cells in a targeted and prolonged manner [19 21] . As the induction of CTL responses is difficult to achieve with peptides alone, the addition of potent immune enhancing adjuvants like cytosine phosphorothioate guanine oligodeoxynucleotides (CpG ODN) or polyriboinosinic:polyribocitidylic acid (polyI:C) is necessary. For the generation of a potent immune response TLR ligand and antigen need to be coencapsulated into the same PLGA MS to end up in the same endosome [22] .
In the present study, we established a potent CTL based immuniza tion protocol against pandemic influenza A virus (H1N1pdm09) using biodegradable PLGA MS. We found that immunization with PLGA MS encapsulating the antigenic peptide M1 58-66 elicits strong and sustained CTL responses. To prevent antigenic drift more than one antigenic peptide could be encapsulated into the same PLGA MS. Furthermore, we could show that the immunization route is critical for the vaccination efficiency and depends on the infection route of each virus. For protection against influenza A virus, we optimized the immunization protocol to a subcutaneous prime vaccination followed by an intranasal boost vaccina tion. This vaccination reduced disease severity in our experiments and hence might help to control pandemic outbreaks of influenza A virus.
Materials and methods

Preparation of microspheres
MS were prepared from 14 kDa PLGA 50:50 carrying hydroxyl and carboxyl end groups (Resomer® RG502H, Evonik Röhm GmbH). The peptides M1 58-66 and PA 46-54 from influenza A virus and TLR ligands were microencapsulated by spray drying as described elsewhere [23] . Briefly, 2.5, 5, 10 or 20 mg M 58-66 peptide and 5 mg CpG oligodeoxynucleotides with a phosphorothioate backbone (CpG ODN 1826, Microsynth) or 0.5 mg polyI:C (Sigma Aldrich) were dissolved in 0.5 ml 0.1 M NaHCO 3 and mixed with 1 g of PLGA dissolved in 20 ml dichloromethane. Coencapsulation of M1 58-66 and PA 46-54 peptides was performed by co dissolving 10 mg M1 58-66 and 10 mg PA 46-54 with 5 mg CpG ODN in 0.5 ml of 0.1 M NaHCO 3 and 1 g PLGA in 20 ml dichloromethane. The aqueous and the organic phase were homogenized under ultrasonication. The obtained w/o dispersion was immediately spray dried (Mini Spray dryer 191, Büchi) at a flow rate of 2 ml/min and inlet/outlet temperature of 40°C/37°C. The obtained MS were washed out of the spray dryer's cyclone with 0.05% poloxamer 188 (Synperonic®F68, Serva Electrophoresis), collected on a cellulose acetate membrane filter and dried under reduced pressure (20 mbar) for 18 h at room temperature. MS were stored at 4°C. Immediately before use, MS were dispersed in PBS by ultrasonication for 30 s to obtain a homogenous MS solution.
Characterization of the microspheres
To characterize the PLGA MS, encapsulation efficiency and release of the two peptides was analyzed. For the determination of the encapsula tion efficiency, 5 mg MS were dissolved in 200 μl acetone. The solvent was evaporated with vacuum centrifugation and the pellet was resus pended in MilliQ water under ultrasonication. Release of the peptides from the PLGA MS was identified by dispersing 5 mg PLGA MS in 200 μl PBS by ultrasonication for 30 s. After incubation at 37°C under agitation for 6 days, samples were spun down. Peptide contents of the supernatants were determined using the MicroBCA™ Protein Assay Kit (Life Technolo gies) according to the manufacturer's protocol using the respective peptide as standard. The assessed amounts were compared to theoretical maximal loading and given in % encapsulation efficiency.
Mice and immunizations
HLA A*0201 transgenic mice (AAD mice) were originally obtained from Charles River Laboratories. All mice were kept in a specific pathogen free facility and used at 6 Berlin, Germany. The virus was further propagated in human lung adenocarcinoma epithelial cells (A549).
Isolation of cells
Splenocytes were isolated by mechanical disruption. For isolation of lung lymphocytes, lungs were washed with PBS, cut into small pieces and digested at 37°C in IMDM containing 0.2 mg/ml of collagenase D (Roche), 0.2 mg/ml of DNase I (Roche), 10% FCS, 100 U/ml P/S for 45 min at 37°C under agitation. Cells were gently pressed through a mesh, washed and re suspended in 36% Percoll® in PBS (Sigma Aldrich). The cell suspension was gently overlaid onto 70% Percoll® and centrifuged for 30 min at 1.350 ×g at 4°C. Lymphocytes were collected from the interface.
Intracellular cytokine staining
Intracellular cytokine staining (ICS) was performed to detect intracellular interferon gamma (IFN γ) as a measure of CTL activation. Isolated splenocytes or lung lymphocytes were incubated with or without 10 μM of the respective peptide or an irrelevant control peptide in the presence of 10 μM/ml brefeldin A (Sigma Aldrich) for 5 h at 37°C. After washing, the cells were stained with APC conjugated rat anti mouse CD8α antibody clone 53 6.7 (eBioscience) for 20 min at 4°C. The cells were washed twice before they were fixed with 4% paraformaldehyde in PBS for 5 min at 4°C. Afterwards, cells were washed twice with PBS/0.1% saponin for permeabilization and were then labeled intra cellularly with FITC conjugated rat anti IFN γ antibody (clone XGM1.2) in PBS/0.1% saponin overnight at 4°C. The next day, cells were washed twice and were resuspended in PBS for flow cytometry. Background values of each sample (no restimulation with peptide) were subtracted.
ELISPOT
A commercially available antibody pair (BD Biosciences) for the detection of IFN γ producing cells was used according to the manufacturer's protocol. ELISPOT 96 well plates were coated with anti IFN γ antibody and subsequently blocked. Splenocytes were incu bated with or without 10 μM of the respective peptide overnight. After incubation with a biotinylated antibody for 2 h, a streptavidin alkaline phosphatase enzyme conjugate was added for 40 min at room tempera ture. Spots of the dried plate were counted using an ImmunoScan instru ment (C.T.L., Cellular Technology Ltd.).
Vaccinia virus infection and protection assay
To assay viral protection, AAD mice were immunized s.c. with a mixture of 5 mg MS loaded with M1 58-66 peptide (50 μg) and CpG ODN (25 μg) and 5 mg polyI:C MS (2.5 μg). On day 6 after immunization mice were challenged i.p. with 2 × 10 6 pfu recombinant vaccinia virus coding for M1 58-66 (rVV ESM1). Four days later, ovaries were taken, sin gle cell suspensions were prepared by physical disruption in MEM, 5% FCS and analyzed by plaque assay after 6 freeze thaw cycles. Suspensions were titrated and added to confluent BSC 40 cells. After infection, BSC 40 cells were incubated for 24 h at 37°C, 5% CO 2 . After removal of the medium, plaques were visualized by addition of 0.5% crystal violet solution for 1 h, counted, and the pfu were calculated.
Influenza virus infection
On day 6 after the last MS immunization, mice were anesthetized by intraperitoneal injection of 150 μl of a ketamine (Sanofi) rompun (Bayer) solution (equal volumes of a 2% rompun solution and a 10% ketamine solution were mixed at the rate of 1:10 with PBS), before intranasal inoculation with the influenza A virus strain A/ Regensburg/D6/09 (H1N1pdm09, RB1). For infection, a 10 × 50% mouse lethal dose (MLD 50 ) was used (10 × MLD 50 = 5 × 10 4 pfu in C57BL/6 mice). For determination of the clinical score, the following disease symptoms were found and defined: ruffled fur, teeth crunching, ataxia, dyspnea and conjunctivitis. If mice showed one of the aforementioned symptoms they received one score; 2 symptoms = score 2; 3 and more symptoms = score 3 and death = score 4. Note, score 4 was kept throughout the observation period. Score represents the mean value of the group. Furthermore, mice were weighted daily. When mice were euthanized at the clinical end point of 75% of the initial bodyweight, the bodyweight at the endpoint was kept throughout the observation period. 
Influenza virus plaque assay
To assess the number of infectious particles in the lungs, a plaque assay using AVICEL® was performed in 96 well plates as described previously [24] 48 h after infection. Briefly, Madin Darby canine kidney (MDCK II) cells were grown to confluency in 96 well dishes, then they were washed with PBS and infected with serial dilutions of the superna tants in PBS/BA for 30 min at 37°C. After incubation, cells were overlaid with overlay medium [1:1, MEM medium containing 0.2% BSA, antibiotics and 2.5% AVICEL® Medium (FMC BioPolymer)] for 24 h. Afterwards, virus infected cells were immunostained by incubating for 1 h with a monoclonal antibody specific for the influenza A virus nucleoprotein (Serotec), followed by 30 min incubation with peroxidase labeled anti mouse antibody (DIANOVA) and 10 min incubation with True Blue™ peroxidase substrate (KPL). Stained plates were scanned on a flatbed scanner and the data were acquired by Corel DRAW 9.0 software. Viral titers are shown as the logarithm to the base 10 of the mean values.
Statistics
For statistical analyses, groups from similar experiments were pooled and analyzed for significant differences as indicated in the graph. The p values for experiment composites are given in the figure legends. All statistical analyses were performed using Prism software (GraphPad Software, Inc.).
Results
High immunogenicity of PLGA MS based immunization with the influenza A virus epitope M1 58-66
To investigate the feasibility and potency of eliciting CTL responses to influenza A virus the highly conserved synthetic M1 58-66 peptide epitope of influenza virus matrix 1 protein was encapsulated together with the CpG oligodesoxynucleotide 1826 into biodegradable PLGA microspheres. First of all, the generated M1/CpG MS were characterized regarding their peptide encapsulation efficiency and peptide release. Compared to the theoretical maximal loading, around 45% of the peptide was encapsulated into the MS and during the first 6 days around 7% of the peptide was released in aqueous medium (Fig. 1A) . Next, the immunogenicity of an immunization with these MS was addressed. For this purpose HLA A*0201 transgenic AAD mice were s.c. immunized with a mixture of M1 58-66 /CpG MS and polyI:C MS. Six days after the immunization, a strong induction of antigen specific CTLs was measureable in the spleen (Fig. 1B+C ). While immunization with microspheres containing only the adjuvants CpG ODN and polyI:C induced only a minor response due to unspecific stimulation, no IFN γ secretion was detectable after immunization with empty microspheres. In contrast, no IFN γ producing, antigen specific CTLs could be induced in C57BL/6 mice emphasizing the HLA A*0201 restriction of the M1 58-66 epitope (Fig. 1D) . These data show the high immunogenic potential of a PLGA MS based immunization with the influenza virus epitope M1 58-66 and the Th1 polarizing TLR ligands CpG ODN and polyI:C.
MS induce strong and sustained immune responses in vivo
To determine the optimal peptide amount for vaccination with PLGA MS, AAD mice received a single injection of MS containing 12.5, 25, 50 or 100 μg M1 58-66 peptide co encapsulated with 25 μg CpG ODN in a mixture with polyI:C MS (2.5 μg). The lowest peptide concentration already induced a robust immune response in the spleens of immunized mice after 6 days (Fig. 2A+B) . The number of M1 58-66 specific, IFN γ secreting CD8 + T cells increased corresponding to the peptide amount encapsulated in the MS until a plateau was reached for a peptide concentration of 50 μg per mouse. The MS containing 100 μg M1 58-66 peptide did not induce a higher immune response, which could be due to a limited encapsulation efficacy or a peptide saturation of the T cells. As a further characteristic of MS based vaccination the immune response kinetics were analyzed (Fig. 2C) . Therefore, AAD mice were immunized with an optimal peptide concentration of 50 μg M1 58-66 peptide per mouse. On day four after immunization, no peptide specific CTLs were detectable. The peak of the immune response could be measured between day 6 and day 8. There was a decreasing but persistent CTL response at least until the last time point of the measurement on day 35. The best vaccination protocol was found to be an immunization of the AAD mice with MS containing 50 μg M1 58-66 peptide and CpG ODN (25 μg) in combination with polyI:C MS (2.5 μg).
Co encapsulation of two peptide antigens does not diminish the elicited immune response
Immune escape by antigenic drift reduces the reliability of vaccination against influenza virus. Therefore, it is advantageous to encapsulate more than one peptide antigen into MS. As it was shown before that antigen and the Toll like receptor ligand need to be co encapsulated into one MS [22] we tested if two peptide antigens can be encapsulated together with CpG ODN into one MS with the same efficacy. PA 46-54 derived from the RNA polymerase was used as a second peptide, which like M1 58-66 is a naturally processed, HLA A*0201 restricted and highly conserved epitope of influenza virus [25] . First of all, we could show that 27% of the theoretical maximal loading of PA 46-54 was encapsulated into the MS and 9% of the maximal loading was released during incuba tion at 37°C for 6 days from PA 46-54 /CpG MS (Fig. 3A) . PA 46-54 /CpG MS mixed with polyI:C MS were highly immunogenic in AAD mice and induced a strong peptide specific CTL response in spleens of vaccinated mice (Fig. 3B+C) (Fig. 3D) . Accordingly, co encapsulation of two peptide epitopes into the same MS did not diminish the elicited CTL responses to each of them.
Vaccination with PLGA MS protects mice from infection with a recom binant vaccinia virus
In the first instance, we compared the potency of a PLGA MS based vaccination to an immune response elicited by a viral infection. Therefore, AAD mice were immunized with MS carrying M1 58-66 peptide and CpG ODN mixed with polyI:C MS or were infected with a recombinant vaccinia virus coding for the M1 protein (rVV M1) or the M1 58-66 epitope (rVV ESM1). While immunization with PLGA MS induced a strong and robust CTL response, a rather low response was recorded after infection with the recombinant vaccinia virus (Fig. 4A) .
Infection with vaccinia virus is a good model for investigating immune mediated viral protection, as it depends on the activity of CTLs. Hence, we compared the antiviral capacity of mice immunized with M1 58-66 /CpG containing MS and polyI:C MS with control mice that received CpG MS and polyI:C MS. Mice were challenged with 1 × 10 6 pfu vaccinia virus on day 6 after immunization and virus titers were determined 4 days later in the ovaries. Vaccination with M1 58-66 /CpG MS and polyI:C MS led to a complete clearance of vaccinia virus (Fig. 4B) . In contrast, control mice showed high rVV ESM1 titers in the ovaries. Taken together, vaccination with PLGA MS induced protection against vaccinia virus in an antigen specific manner.
Single vaccination with PLGA MS does not allay influenza virus infection
Protective immunity against influenza virus after vaccination and natural infection is primarily mediated by antibody responses against viral surface proteins. However, reduced disease severity can be achieved with strong T cell responses to internal viral proteins [26] . After having successfully demonstrated the antiviral capacity of PLGA MS in a vaccinia virus infection model, we investigated whether vaccination with PLGA MS can also temper influenza virus infection. To test this, mice were immunized either with PLGA MS containing M1 58-66 /CpG and polyI:C MS or with CpG MS and polyI:C MS as a control for antigen specificity. Six days after immunization mice were inoculated intranasally (i.n.) with 5 × 10 4 pfu H1N1pdm09 influenza virus. After 48 h lungs of mice from both groups were collected and virus titers were determined by plaque assay. There was no reduction of virus titers in the lungs of mice treated with MS containing M1 58-66 compared to the control group (Fig. 5A) . Both groups showed a continuous loss of bodyweight starting from day 2 (Fig. 5B) . Onset of clinical symptoms was at day 4 post infection evolving to score four (death) in both groups (Fig. 5C) . Although s.c. vaccination with PLGA MS has a high immune mediated antiviral capacity during vaccinia virus infection it does not allay influenza virus infection in vivo. 
PLGA MS can induce mucosal and systemic immunity
Systemic vaccination might not be suitable to induce CTLs against influenza virus at the site of infection, the respiratory tract. To overcome these limitations, we evaluated two alternative immunization strategies with the aim to generate both, mucosal and systemic immunity. For the first vaccination scheme AAD mice were primed s.c. with 5 mg peptide (50 μg)/CpG (25 μg) MS and 5 mg polyI:C (2.5 μg) MS in a volume of 200 μl and boosted after 14 d i.n. with half the amount of MS in a volume of 50 μl. For the second vaccination strategy, mice were immunized i.n. with peptide (25 μg)/CpG (12.5 μg) MS and polyI:C (1.25 μg) MS. The same immunization protocols were applied to the control groups that received CpG MS and polyI:C MS. Six days after the last immunization, the numbers of antigen specific CTLs were analyzed in spleen (Fig. 6A) and lung (Fig. 6B) . In the spleen, the highest number of antigen specific CTLs was found for the group that received a single subcutaneous immunization (Fig. 6A, lane 1) . A strong CTL response was also observable in the spleens of mice immunized with M1 58-66 , PA 46-54 , or M1 58-66 / PA 46-54 in the prime boost setting. In contrast, only a minor response could be detected for the group that has received a single i.n. immu nization (Fig. 6A, lane 3) . For both new vaccination protocols no antigen specific CTLs were detectable for the control groups immunized with adjuvant MS. Furthermore, a combination of a s.c. prime vaccination with M1 58-66 /CpG MS and polyI:C MS and an i.n. boost vaccination with adjuvant MS just induced a negligible number of antigen specific CTLs (Fig. 6A, lane 11) . A completely different picture could be observed in the lungs of the immunized mice (Fig. 6B) . Here, the highest number of antigen specific CTLs was measured for M1 58-66 / CpG MS and polyI:C MS applied with the prime boost vaccination set ting (Fig. 6B, lane 5) . In addition, PA 46-54 and M1 58-66 /PA 46-54 administered according to the prime boost vaccination setting could in duce a CTL response, too (Fig. 6B, lane 7) . In contrast, there was only a low response after single s.c. or single i.n. vaccination with M1 58-66 MS (Fig. 6B, lanes 1 and 3) and no measurable response for the control groups. Interestingly, an s.c. antigen specific prime followed by an un specific, inflammatory stimulus in the lung also led to no CTL response in the lung (Fig. 6B, lane 11 ) thus indicating that a successful i.n. boost relies on antigen to accumulate specific CTLs in the lung. Encapsulation of the two peptides into different MS with one TLR ligand each resulted in a slightly higher response in the lung but not in the spleen (Fig. 6B , lanes 9 +10) compared to the M1/PA/CpG MS and polyI:C MS setting (Fig. 6B, lanes 7+8) . In addition, i.n. prime and i.n. boost with M1 MS (Fig. 6B, lane 12) were not as potent as i.n. boost after s.c. prime.
Heterologous vaccination with PLGA MS leads to protective immunity against influenza virus infection
Next, we wanted to investigate if the systemic and mucosal immunity induced by the heterologous prime boost vaccination scheme enables protection against challenge with a lethal dose of influenza virus. Single i.n. immunization with M1 58-66 /CpG MS and polyI:C displayed no protec tive capacity against pandemic influenza virus H1N1pdm09 (Fig. 7A) . High virus titers measured 48 h after infection in the lung correlated with a tremendous weight loss of both groups between days five and six and subsequent infection related death (Fig. 7B/C) . Mice that received a prime boost immunization with PA 46-54 /CpG MS and polyI:C MS showed significantly reduced virus titers compared to the mice immu nized with the adjuvants MS, but were not protected against infection related weight loss and morbidity. Both, mice vaccinated with M1 58-66 and PA 46-54 and CpG co encapsulated into one microsphere mixed with polyI:C MS and mice vaccinated with M1 58-66 /CpG MS and polyI:C MS according to the prime boost setting not only showed both systemic and vigorous CTL responses in the lung (Fig. 6B ) but were also protected from influenza virus infection (Fig. 7B/C) . In accordance with a signifi cantly reduced virus titer in the lung, no weight loss was observable. In summary, vaccination with the conserved and well defined epitopes M1 58-66 and PA 46-54 co encapsulated together with the TLR9 ligand CpG ODN into clinically compatible PLGA microspheres and mixed with microspheres encapsulating the TLR3 ligand polyI:C enable control of influenza A virus infections.
Heterologous vaccination induces sustained immune responses
Immunity against influenza virus should ideally last for at least one influenza season. After vaccination according to our heterologous vacci nation scheme, immune responses were detectable both in spleen and lung for four weeks. Moreover, specific CTLs in lung and spleen could be restimulated with an additional intranasal boost immunization after decay of the initial immune response (Fig. 8A/B) . In the spleen, the number of specific CTLs more than doubled between weeks one and two after the boost immunization, probably due to migration from the lung to the spleen. Between weeks two and four the number of CTLs in the lung remained stable until a strong decrease in week eight (Fig. 8A) . In the lung, equal numbers of specific CTLs were observable during the first three weeks. After eight weeks, no specific CTLs were measurable in the lung anymore (Fig. 8B) . Re boost after eight weeks induced robust CTL responses both in the lung and spleen indicating an efficient formation of T memory cells.
Discussion
The most pivotal task in the fight against a recurrence of an influ enza virus pandemic is the development of a vaccine that induces heterosubtypic protection against all influenza A viruses. Heterosubtypic immunity is mediated by serotype cross reactive CTLs specific for conserved internal proteins like the matrix protein [13, 27] . Induction of CTL responses in contrast to an antibody response is indispensable for the suppression of initial viral replication in the respiratory epithelium [12] and furthermore can provide partial [28, 29] or complete protection of mice from heterosubtypic influenza viruses [30, 31] . CTLs induce apoptosis of virus infected cells after recognizing viral peptides bound to major histocompatibility complex (MHC) class I molecules and secrete antiviral cytokines, notably interferon γ and tumor necrosis factor [32] . Following natural influenza A virus infection the CTL response of HLA A*0201 + individuals (i.e., approx. 50% of the Caucasian population)
is exquisitely focused on the immunodominant M1 58-66 peptide [33, 34] . In our study, we investigated the potency of PLGA MS based vacci nation with M1 58-66 peptide. We could show that PLGA MS containing M1 58-66 peptide and the TLR ligand CpG mixed with polyI:C MS were capable of inducing robust CTL responses in HLA A*0201 transgenic mice after a single subcutaneous vaccination without the need to induce antigen specific T helper cells. Peptide vaccines provide several advantages over the currently used inactivated viral vaccines. Peptides can be easily produced in large scale and bear no risk of infectious particles. In addition, PLGA MS protect the encapsulated peptides from proteolytic degradation, thus a lower antigen dose is required. Further more, the use of PLGA MS as an antigen delivery device provides a depot effect and therefore a prolonged antigen release [19, 35] . This leads to a CTL response that peaks on day 6 and reaches even beyond day 35 after immunization (Fig. 2C) . The promptitude of the CTL response is of special interest, as early viral clearance after influence A virus infection is required for both, significant reduction in the severity of symptoms and the prevention of lethal viral pneumonia [36, 37] . Direct pulsing of DCs with MHC class I restricted influenza virus epitopes without usage of a vaccine delivery system was reported to induce potent antiviral CTL responses though leading to a delayed clearance of an influenza virus challenge [38] . An advantage of peptide vaccines is the fact that they are flexible in their design and can therefore contain more than one antigen, which increases the clonality of the elicited T cell response [14] . As immune escape by antigenic drift is a threat to the potency of a vaccination against influenza virus, it is advantageous to use such a multi epitope vaccine. The only limitation however is the number of different peptides that can be encapsulated into one microsphere. Co encapsulation of the influenza epitopes M1 58-66 and PA 46-54 though led to an equally strong CTL response as single encapsulation of each peptide (Fig. 3C) . Being dependent on CTL activity, protection against vaccinia virus is a good model for viral infection. In fact, we were not only able to show an effective CTL induction by measuring the IFN γ release of antigen specific CD8 + splenocytes but we could also evidence their functionality in viral protection after systemic vaccination with PLGA MS bearing the viral epitope M1 58-66 . However, systemic immuni zation with M1 58-66 containing PLGA MS did neither ease the symptoms nor lead to an extended survival after infection with influenza A virus. It was previously reported that systemic administration of vaccines generally fails to induce mucosal immunity while mucosal immuniza tions have the ability to induce both local and systemic immunity and therefore induce local long term immunological memory at the site of entry [39] . In addition, s.c. immunization does not lead to an instant elimination of the infected airway epithelial cells by the induced CTLs even though i.v. injected target cells are destroyed rapidly [11] . However, intranasal administration of M1 58-66 microspheres neither induced specific CTLs in the spleen nor in the lung of the immunized mice. Wells et al., in contrast, already demonstrated that transferred lympho cytes from previously infected mice migrated to the lungs of the host mice during influenza virus infection and led to an earlier and greater reduction in pulmonary virus titer. On the other hand, transfer of naive lymphocytes to infected mice resulted in a very late reduction of the pulmonary virus titer on day 21 [36] . Additionally, a systemic prime was needed prior to mucosal immunization with microparticles containing simian immunodeficiency virus (SIV) to induce protective immunity in macaques challenged with SIV [40] .
A systemic prime vaccination could also contribute to the establishment of long term memory as it was shown before that the memory T cell population in the lung airways is dynamic and depends on a systemic source of T cells that is continually recruited from the circulation. This implicates a significant connection of memory T cell pools in the secondary lymphoid organs and those in peripheral tissues [41] . In fact, systemic prime vaccination and intranasal boost vaccination resulted in a prominent CTL infiltration of the lung including a significantly higher number of M1 58-66 specific CTLs (Fig. 6B ). Vaccina tion with the two well defined and conserved virus epitopes M1 [58] [59] [60] [61] [62] [63] [64] [65] [66] and PA 46-54 encapsulated into clinically compatible PLGA microspheres contributed to the control of influenza A virus infections and interferes with virus replication, weight loss, and infection related death (Fig. 7) . As intranasal vaccination does not require injection it is less painful and has therefore a high patient compliance. Application would also not require trained medical personnel, which is a great benefit in mass vaccination programs or in countries with poor health care. Interestingly, neither a single intranasal immunization nor a single subcutaneous vaccination was sufficient to induce a robust CTL response in the lung (Fig. 6B) . These results indicate that both, mucosal and systemic immu nity are needed to induce protective immunity in the lung. Single s.c. immunization might not be sufficient, because injected vaccines are generally poor inducers of mucosal immunity. Single i.n. vaccination alone on the other hand could induce tolerance as mucosal surfaces are adapted to the presence of foreign microorganisms. In addition, an inflammatory stimulus in terms of an adjuvant boost after a peptide spe cific prime vaccination also does not lead to a cross protective immunity through migration of antigen specific cells from the lymphoid organs to the lung mucosa. Ninomiya et al. even stated that both MHC class I and class II are necessary after vaccination with a MHC class I restricted influenza virus epitope encapsulated in liposomes and anti CD40 mAb to induce protective immunity against influenza A virus in mice [16] . However, protection against influenza A virus infection through humoral and cell mediated immunity was also reported after s.c. or i.p. immunization of mice with HA split product virus vaccines encap sulated into poly(gamma glutamic acid) graft L phenylalanine nano particles [42] .
The usage of CpG ODN and polyI:C as adjuvants activates innate signaling pathways and helps the vaccine to be distinguished from commensal bacteria. Furthermore, these two TLR ligands generate a strong Th1 polarizing condition, minimizing the probability of unwanted tolerance induction. PLGA MS themselves also help to circumvent toler ance as they are specifically taken up by professional antigen presenting cells. A study by Maroof et al. showed, that intranasal vaccination with a TLR4 agonist and a detergent split influenza antigen promotes antigen specific antibody responses but also polyfunctional antigen specific Th17 cells leading to increased weight loss and morbidity during the early stages of disease [43] . The utilization of CpG ODN and polyI:C in our vaccination protocol, in contrast, generates a strong Th1 polarizing condition, which in combination with the usage of a peptide exclusively presented on HLA A*0201 to CD8 + cytotoxic T cells, limits the danger of the induction of an unwanted Th17 cell mediated, vaccine induced IL 17 response. Consistent with this, no increased weight loss or morbidity was observable for our vaccination. Similarly, Ichihashi et al. already could demonstrate that immunization of HLA A*2420 transgenic mice with liposome conjugated HLA A*2420 restricted influenza virus peptides in the presence of CpG ODN protected from lethal influenza virus challenge. In contrast to our study, a single peptide was not able to mediate this effect, but three epitopes were necessary to induce protection [11] .
Conclusions
In conclusion, we have established a safe and powerful vaccination against influenza virus infection that interferes with virus replication, weight loss and infection related death in a mouse model, which very closely reflects the human situation. This applicable approach could help to foreclose pandemic outbreaks of influenza viruses, especially in countries with high HLA A*0201 allele frequencies like Europe as well as North and South America.
